Meet the 2024 FAST Fall cohort, comprised of twelve innovative startups focused on promising developments in therapeutics, diagnostics, and precision medicine technology. These companies spent several weeks working with our curated network of advisors to develop a compelling commercialization strategy. They presented on December 10 at our Innovation Showcase, where these founders presented to an audience of investors and collaboration partners.
Learn more about our showcase here!
Cenos Therapeutics pioneers neurological health with innovative RNA therapeutics, utilizing systemically dosed conjugate RNA technology for deep brain delivery
June Park, PhD
Email: [email protected]
Our mission is to accurately rule in or out ovarian cancer earlier when it’s easier to treat and improve the treatment planning of women with ovarian masses.
Bodour Salhia, PhD
Email: [email protected]
IHP Therapeutics is developing the first disease-modifying therapeutic for on-demand treatment of acute vaso-occlusive crises in patients with sickle cell disease.
Mr. Rinko Ghosh, MS, MBA
Email: [email protected]
Eximius Diagnostics is developing extracellular vesicle (EV) based liquid biopsy tests for cancer diagnosis and treatment monitoring.
Hsian-Rong Tseng, PhD
Email: [email protected]
Lucidify is a neurotechnology company that continuously monitors brain activity from just a few sensors, detects brain failure (delirium) with advanced, edge-based machine learning algorithms, and preserves cognitive longevity and mental health by identifying biomarkers that signal the need to treat underlying disorders.
Divya Chander, MD, PhD
Email: [email protected]
Neuro Industry builds foundation models trained on brainwave data to understand and detect brain activity, with applications in psychiatric care, neuroscience research, and personalized mental health treatments.
Aidan Tsai
Email: [email protected]
Harnessing human nose-to-brain pathway for brain disease treatments.
Parnian Lak, PhD
Email: [email protected]
Orbits Oncology uses AI to analyze the most human-like tumor models, called organoids, for digital transformation in drug discovery.
Abraham Lin, PhD
Email: [email protected]
Sift Biosciences develops next-generation immunomodulators to treat cancer and autoimmune diseases.
Yue Clare Lou, PhD
Email: [email protected]
TippingPoint Biosciences is an early stage therapeutic company with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin).
Laura Hsieh, PhD
Email: [email protected]
Safely Unlocking the Killing Power of Macrophages with Tumor-Activated Biologics.
Ugur Eskiocak, PhD
Email: [email protected]
Radar Therapeutics develops exquisitely specific genetic medicines through its platform for selectively activated mRNAs. Radar is uniquely enabled to precisely control the expression and activity of genetic medicines at the cell type or even cell state level, thereby revolutionizing treatment for a broad array of autoimmune, oncological, and rare diseases. The company spun out of the labs of Stanford Prof Xiaojing Gao and MIT Prof Jim Collins, and is led by CEO Sophia Lugo and CSO Eerik Kaseniit.
Radar Therapeutics was selected to receive the Wacker Biotech Discovery Award, receiving $100,000 of in-kind credits to work with Wacker Biotech along with the opportunity to give a company presentation at the CLS Innovation Showcase taking place December 10 in South San Francisco.